› Forums › General Melanoma Community › June to apply for U.S. approval – MK-3475
- This topic has 6 replies, 2 voices, and was last updated 11 years, 4 months ago by
Nadia.
- Post
-
- February 6, 2014 at 8:33 am
Merck said it expects by June to apply for U.S. approval to sell the drug for advanced melanoma.
The drug, known as MK-3475,is part of a promising new class of cancer “immunotherapy” designed to make the immune system regain its ability to identify and then target cancer cells.
In some cancer types, the tumor cells often have a protein on their surface called PD-L1 that essentially acts as an invisibility cloak. Merck’s MK-3475 and similar drugs can block that protein, or a corresponding one called PD-1 found on T cells, a crucial immune system component, thus making tumor cells visible.
Viewing 5 reply threads
- Replies
Viewing 5 reply threads
- You must be logged in to reply to this topic.